CBMS navigation bar CBMS link JVAP link BSV link CRP link

Medical Identification and Treatment Systems (MITS)

About
The CBMS-Medical Identification and Treatment Systems (MITS) provides the Warfighter and the Nation with robust, affordable, U.S. Food and Drug Administration (FDA)–approved lifesaving medical countermeasure drug capabilities against chemical, biological, radiological, and nuclear threats. The CBMS-MITS serves as the life cycle product manager for the following fielded products: Convulsant Antidote for Nerve Agents (CANA), Antidote Treatment Nerve Agent Autoinjector (ATNAA), and Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP).
MITS Logo

The CBMS-MITS' advanced development efforts include Bioscavenger (BSCAV), Advanced Anticonvulsant System (AAS), Improved Nerve Agent Treatment System (INATS), Inhalation Atropine (IA), and Medical Radiation Countermeasures (MRADC). A future advanced development effort, the Centrally–Acting Nerve Agent Treatment System (CANATS), is preparing for transition to MITS from the technology base.

Mission
To rapidly provide the Warfighter and the Nation robust and affordable U.S. Food and Drug Administration (FDA)–approved lifesaving medical countermeasure drug and diagnostic system capabilities against chemical, biological, radiological, and nuclear (CBRN) threats. MITS products range from specific hardware devices, which enable medical personnel to diagnose specific biological warfare agent exposure, to drugs that will prevent or mitigate the actions of chemical, radiological, or nuclear threats.

Products  
Advanced Anticonvulsant Systems (AAS) Antidote Treatment – Nerve Agent, Autoinjector (ATNAA)
Bioscavenger (BSCAV) Soman Nerve Agent Pretreatment
Pyridostigmine (SNAPP)
Inhalation Atropine (IA) Medical Radiation Countermeasures (MRADC)
Improved Nerve Agent Treatment System (INATS)  

MITS Capabilities Image

Contact Information
Phone: 301.619.7085
E-mail: usarmy.detrick.cbms.mbx.info@mail.mil

Last updated: 8/29/2012 9:35:08 AM